Published on 29 Nov 2023 on Simply Wall St. via Yahoo Finance
Insiders who bought US$1.95m worth of Cyclerion Therapeutics, Inc.'s (NASDAQ:CYCN) stock at an average buy price of US$8.68 over the last year may be disappointed by the recent 16% decrease in the stock. Insiders purchase with the hope of seeing their investments increase in value over time. However, due to recent losses, their initial investment is now only worth US$429.8k, which is not great.
While insider transactions are not the most important thing when it comes to long-term investing, logic dictates you should pay some attention to whether insiders are buying or selling shares.
See our latest analysis for Cyclerion Therapeutics